Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ester doai
Patent
1992-12-08
1995-06-06
Gerstl, Robert
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ester doai
A61K 31557
Patent
active
054223687
ABSTRACT:
The invention relates to ophthalmological compositions for topical treatment of glaucoma or ocular hypertension comprising an effective intraocular pressure reducing amount of a prostaglandin derivative of PGA, PGB, PGD, PGE or PGF, in which the omega chain contains a ring structure, in an ophthalmologically compatible carrier. The invention further relates to the preparation of said compositions and their use for treatment of glaucoma or ocular hypertension.
REFERENCES:
patent: 3956284 (1976-05-01), Hess et al.
patent: 3962312 (1976-06-01), Hayashi et al.
patent: 3987087 (1976-10-01), Bundy
patent: 4001300 (1977-01-01), Axen
patent: 4011262 (1977-03-01), Hess et al.
patent: 4115586 (1978-09-01), Miller, Jr.
patent: 4116988 (1978-09-01), Nelson
patent: 4117119 (1978-09-01), Kurono et al.
patent: 4128713 (1978-12-01), Schneider
patent: 4131738 (1978-12-01), Smith
patent: 4599353 (1986-07-01), Bito
patent: 4820728 (1989-04-01), Collins et al.
patent: 4824857 (1989-04-01), Goh et al.
patent: 4883819 (1989-11-01), Bito
patent: 5001153 (1991-03-01), Ueno et al.
patent: 5057621 (1991-10-01), Cooper et al.
patent: 5151444 (1992-09-01), Ueno
Starr, M. S. (1971) "Further studies on the effect of prostaglandin on intraocular pressure in the rabit", Exp. Eye, Res. 11:170.
Kass, M. A., Posos, S. M., Moses. R. A., and Becker B. (1972): "Prostaglandin E1 and aqueous humor dynamics", Invest Ophthalmol. 11:1022.
Villumsen J. and Alm A. (1987): "The effect of prostaglandin F2.sub..alpha. eye drops in open angle glaucoma", Invest Opthalmol. Vis. Sci. 28:378.
Wang R.-F., Cmamras C. B., Lee P.-Y., Podos S. M. and Bito L. Z. (1987) "The ocular hypotensive effects of Prostaglandins F2.sub..alpha. isopropyl ester and A2 in glautomatous monkeys" Invest Ophthalmol Vis Sci ARVO Supl. 28:266.
Kass M. A., Mandell Al, Goldberg I., Paine J. M. and Becker B. (1979) "Dipivefrin and epinephrine treatment of elevated intraocular pressure: A comparative study", Arch Ophthalmol. 97:1865.
Goldberg I., Kolker A. E., Kass M. A. and Becker B. (1980) "Dipivefrin: current concepts", Australia J. Ophthalmol., 8:147.
Bill A. (1975) "Blood Circulation and fluid dynamics in the eye". Physiol. Rew. 55: 383-417.
Bito L. Z., Draga A., Blanco D. J., Camras C. B. (1983) "Long Term Maintenzance of Reduced intraocular Pressure by Daily or Twice Daily Topical Application of Prostaglandins to Cat or Rhesus Monkey Eyes" Invest. Ophthalmol. Vis. Sci. 24: 312-319.
Bito L. Z., Camras C. B., Gum G. G. and Resul B. (1989). "The Ocular Hypotensive Effects and Side Effects of Prostaglandins on the Eyes of Experimental Animals" Progress in Clinical and Biological Research 312 Ed. L. Z. Bito and Johan Stjernschantz, A. R. Liss, Inc., New York.
Burke et al., "Prostaglandin F.sub.2.alpha. Effects on Rabit IOP Negatively Correlate with Classical PGF.sub.2.alpha. -Receptor" Stimulation Presented at ARVO annual meeting in Florida May 1-6, 1988.
Bundy, Chem Abst. 90:168141d, 1979.
Camras C. B., Bito L. Z. (1981). Reduction of intraocular pressure in normal and glaucomatous primate (Aotus trivirgatus) eyes by topically applied prostaglandin F.sub.2.alpha.. "Curr Eye Res" 1:205-209.
Camras, C. B., Podos S. M., Rosenthal J. S., Lee P. Y., Severin C. H. (1987a). Multiple dosing of prostaglandin F.sub.2.alpha. or epinephrine on cynomolgus monkey eyes. I. Aqueous humor dynamics.Invest Ophthalmol Vis Sci 28:463-469.
Camras C. B., Bhuyan K. C., Podos S. M., Bhuyan D. K. Master R. W. P. (1987b) "Multiple Dosing of Prostaglandin F.sub.2.alpha. or epinephrine on cynomologus mokey eyes. II. Slitlamp biomicroscopy, aqueous humor analysis, and fluorescein angiography." Invest. Ophthalmol. Vis. Sci. 28: 921-926.
Camras C. B., Siebold E. C., Lustgarten, J. S., Serle J. B., Frisch S. C., Podos S. M., Bito L. Z. (1988) "Reduction of IOP by prostaglandin F.sub.2.alpha. -1-isopropyl ester topically applied in glaucoma patients", Ophthalmology 95(Suppl.) 129 [This article is referenced in the specification, and was raised as prior art in an opposition to Australian patent application 625096, which is related to the instant application. However, we have been unable to locate a copy of this article].
Crawford K., Kaufman P. L. and True Gabel, B. A. (1987), "Pilocarpine antagonizes PGF.sub.2.alpha. -induced ocular hypotension: Evidence for enhancement of uveoscleral outflow of PGF.sub.2.alpha. "-Invest. Ophthalmol. Vis. Sci. (Supp.) ARVO Abstracts 11.
Crawford, K. and Kaufman, P. L., (1987) "Pilocarpine Antagonizes Prostaglandin F.sub.2.alpha. -Induced Ocular Hypotension in Monkeys" Arch. Ophthamology 105 1112.
Flach A. J., Elisason J. A. (1988). "Topical prostaglandin E.sub.2 effects on normal human intraocular pressure". J. Ocu. Pharmacol. 4:13-18.
Gabelt, B. and Kaufman, P. L., (1989) "Prostaglandin F.sub.2.alpha. Increases Uvelscleral Outflow in the Cynomologus Monkey", Exp. Eye Res. 49 389-402.
Giuffre G. (1985). "The effects of prostaglandin F.sub.2.alpha. in the human eye." Graefes Arch Clin. Exp. Ophthalmol. 222:139-141.
Granstrom, E., (1975) "Metabolism of 17-Phenyl-18,19,20-Trinor-Prostaglandin F.sub.2.alpha. in the Cynomolgus Monkey and the Human Female", Prostaglandins 9:19-45.
Kaufman P. L. (1986). "Effects on intracamerally infused prostaglandins on outflow facility in cynomolgus monkey eyes with intact or retrodisplaced ciliary muscle." Exp. Eye Res. 43:819-827.
Kerstetter J. R., Brubaker R. F., Wilson S. E., Kullerstrand L. J. (1988). "Prostaglandin F.sub.2.alpha. -1-isopropylester lower intraocular pressure without decreasing aqueous humor flow." Am. J. Ophthalmol. 105:30-34.
Kirk-Othmar "Encyclopedia of Chemical Technology", 3d Ed. Supplement Volume 711-752 (1984).
Lee, P.-Y., Shae H., XZu L., Qu C.-K. (1988). "The effect of prostaglandin F.sub.2.alpha. on intraocular pressure in normotensive human subjects." Invest Ophthalmol. Vis. Sci. 29:1474-1477.
Miller, "Biological Activities of 17-phenyl-18,19,20-trinorprostaglandins", Prostaglandins 9 9-18 (1975).
Nilsson S. F. E., Stjernschantz J. and Bill A. (1987) "PGF.sub.2.alpha. increase uveoscleral outflow". Invest. Ophthalmol Vis. Sci. Suppl. 284.
Villumsen J. Alm. A. (1989) "Prostaglandin F.sub.2.alpha. isopropylester eye drops. Effects in normal human eyes." Br. J. Ophthalmol. 73:419-426.
Yankee, Chem Abst. 88:62048x, 1978.
Woodward et al., "Prostaglandin F.sub.2.alpha. Effects on IOP Negatively Correlate with Classical PGF.sub.2.alpha. -Receptor" Stimuluation Presented in Eightly International Congress of Eye Research in San Francisco Sep. 4-8, 1988.
Woodward et al. (1989) "Prostaglandin F.sub.2.alpha. Effects on Intraocular Pressure Negatively Correlate with FP-Receptor Stimulaiton" Invest. Ophthal. 30(8) 1838-1842.
Camras C. B., Bito L. Z. and Eakins K. E. (1977): "Reduction of intraocular pressure by prostaglandins applied to the eyes of concious rabbits", Invest Ophthalmol Vis. Sci, 16:1125.
Kerstetter J. R., Brubaker R. F., Wilson S. E. and Kullerstrand B. S. (1987): "Prostaglandin F2 alpha 1-isopropyl ester effects on aqueous humor dynamics in human subjects", Invest Ophthalmol Vis Sci Suppl, 28:266.
Kerstetter J. R., Brubaker R. F., Wilson S. E. and Kullerstrand L. (1988) "Prostaglandin F2.alpha.-1-Isoproplyester Lowers Intracolor Pressure Without Decreasing Aqueous Humor Flow". Am. J. Ophthalmology 105. 30-34.
Bito, Baroody and Miranda (1987): "Eicosanoids as a new class of ocular Hypotensive agents. The apparent therapeutic advantage of derived Prostaglandins of the A and B type as compared with primary prostaglandins of the E, F and D types", Experimental Eye Reaserch, 44:825.
Villumser J., Alm A., Soderstrom M., (1989) "Prostaglandin F2.sub..alpha. -isopropylester Eye Drops: Effect on Intraocular Pressure in Open Angle Glaucoma", Brit. J. Ophthalmology 73, 975-79.
Ritch, Shields and Krupin (1989): "The Glaucomas", C. V. Mosby, p. 561.
Supplement to Investigative Ophthalmology and Visual Science 22 39 (1982), L. Z. Bito, A. Draga J. Blanco, and C. B. Camras, "Maintenance of Reduced Intraocular Pressure (IOP) for several Months by topical application of prostaglandin (PG) E to Eyes of Train
Resul Bahram
Stjernschantz Johan W.
Gerstl Robert
Kabi Pharmacia AB
LandOfFree
Prostaglandin derivatives for the treatment of glaucoma or ocula does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Prostaglandin derivatives for the treatment of glaucoma or ocula, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Prostaglandin derivatives for the treatment of glaucoma or ocula will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-988009